West Pharmaceutical Services, Inc.

WST Healthcare Medical Instruments & Supplies

West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.

Revenue
+8.69%
EPS
+56.7%
Free cash flow
+12.3%
Total debt
+0.10%

Quarter to September 2026, against a year earlier

398.55 6.07 +1.55%
Market cap
$27.3B
P/E
43.8×
Fwd P/E
48.1×
Dividend yield
0.22%
F-score
8/9
Altman Z
13.89
Beneish M
−2.79
Dividend safety
100/100

West Pharmaceutical Services, Inc. (WST) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 6 added · 4 removed · 34 modified
P2I1A: no changes
8-K Oct 29, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Oct 26, 2026 1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 27 added · 5 removed · 26 modified
P2I1A: no comparison — the earlier filing's Item cannot be compared
8-K Jul 23, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jul 14, 2026 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K May 31, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits Officer departure
8-K/A May 7, 2026 1.05 Material cybersecurity incident; 9.01 Financial statements and exhibits
8-K May 7, 2026 1.05 Material cybersecurity incident; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits Cybersecurity incident
8-K May 4, 2026 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026 P1I2: 10 added · 29 removed · 34 modified
P2I1A: no material changes, the filing says
8-K Apr 23, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Mar 9, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 2 added · 3 removed · 18 modified
1A: 6 added · 1 removed · 14 modified
7: 9 added · 12 removed · 28 modified
8-K Feb 12, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025 P1I2: 2 added · 2 removed · 29 modified
P2I1A: no material changes, the filing says
8-K Oct 23, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Sep 11, 2025 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025 P1I2: no comparison — the earlier filing's text is no longer kept
P2I1A: no material changes, the filing says
8-K Jul 24, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K Apr 24, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 13, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 24, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Jul 25, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Apr 25, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Feb 15, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.